Targeting the Ubiquitin–Proteasome System and Recent Advances in Cancer Therapy
Cells · 22.12.2023 · 13 (1) · 29
DOI: 10.3390/cells13010029 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 22.12.2023. Verfasst von Daniela Spano und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Endocrinology and Experimental Oncology "G. Salvatore", National Research Council, Via Pietro Castellino 111, 80131 Naples, Italy. Hauptthemen laut MEDLINE: Neoplasms, Proteasome Endopeptidase Complex. Die Arbeit wurde bisher 82-mal zitiert (Crossref) und nennt 189 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CNR project.
Abstract (Originalsprache)
Ubiquitination is a reversible post-translational modification based on the chemical addition of ubiquitin to proteins with regulatory effects on various signaling pathways. Ubiquitination can alter the molecular functions of tagged substrates with respect to protein turnover, biological activity, subcellular localization or protein–protein interaction. As a result, a wide variety of cellular processes are under ubiquitination-mediated control, contributing to the maintenance of cellular homeostasis. It follows that the dysregulation of ubiquitination reactions plays a relevant role in the pathogenic states of human diseases such as neurodegenerative diseases, immune-related pathologies and cancer. In recent decades, the enzymes of the ubiquitin–proteasome system (UPS), including E3 ubiquitin ligases and deubiquitinases (DUBs), have attracted attention as novel druggable targets for the development of new anticancer therapeutic approaches. This perspective article summarizes the peculiarities shared by the enzymes involved in the ubiquitination reaction which, when deregulated, can lead to tumorigenesis. Accordingly, an overview of the main pharmacological interventions based on targeting the UPS that are in clinical use or still in clinical trials is provided, also highlighting the limitations of the therapeutic efficacy of these approaches. Therefore, various attempts to circumvent drug resistance and side effects as well as UPS-related emerging technologies in anticancer therapeutics are discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Endocrinology and Experimental Oncology "G. Salvatore", National Research Council, Via Pietro Castellino 111, 80131 Naples, Italy.
- Institute of Biochemistry and Cell Biology, National Research Council, Via Pietro Castellino 111, 80131 Naples, Italy.
ORCID-Profile: Daniela Spano
Förderung
- CNR project
Zitieren
APA
Spano, D., & Catara, G. (2023). Targeting the Ubiquitin–Proteasome System and Recent Advances in Cancer Therapy. Cells, 13(1), 29. https://doi.org/10.3390/cells13010029
Vancouver
Spano D, Catara G. Targeting the Ubiquitin–Proteasome System and Recent Advances in Cancer Therapy. Cells. 2023;13(1):29. doi:10.3390/cells13010029
BibTeX
@article{Spano2023,
author = {Spano, Daniela and Catara, Giuliana},
title = {Targeting the Ubiquitin–Proteasome System and Recent Advances in Cancer Therapy},
journal = {Cells},
year = {2023},
volume = {13},
number = {1},
pages = {29},
doi = {10.3390/cells13010029}
}
EUVIMED